Tag Archives: DSM-III

Harvard Expert Ties Mental Illness “Epidemic” to Big Pharma’s Agenda

For any mental illness or passing mood swing that may trouble a person, the Diagnostic and Statistical Manual of Mental Disorders — better known as the DSM — has a label and a code. Recurring bad dreams? That may be a Nightmare Disorder, or 307.47. Narcolepsy uses the same digits in a different order: 347.00. Fancy feather ticklers? That sounds like Fetishism, or 302.81. Then there’s the ultimate catch-all for vague sadness or uneasiness, General Anxiety Disorder, or 300.02. That’s a label almost everyone can lay claim to.Drug companies are particularly eager to win over faculty psychiatrists at prestigious academic medical centers. Called “key opinion leaders” (KOLs) by the industry, these are the people who through their writing and teaching influence how mental illness will be diagnosed and treated. They also publish much of the clinical research on drugs and, most importantly, largely determine the content of the DSM. In a sense, they are the best sales force the industry could have, and are worth every cent spent on them. Of the 170 contributors to the current version of the DSM (the DSM-IV-TR), almost all of whom would be described as KOLs, ninety-five had financial ties to drug companies, including all of the contributors to the sections on mood disorders and schizophrenia.

Psychiatry & the United States of Affliction: Are You Normal or Finally Diagnosed?

Spend just a few minutes watching prime time television with its endless pageant of commercials for antidepressants and anti-anxiety meds and you start to wonder if USA really means the United States of Affliction. Such “direct to consumer” drug advertising ties into one of the most far-reaching criticisms in revising the Diagnostic and Statistical Manual of Mental Disorders…

70% of psychiatrists in charge of adding new mental disorders to psych billing bible (DSM) have conflicts/ties to Pharma

Former editors of the Diagnostic and Statistical Manual of Mental Disorders (DSM) have publicly declared their concerns that the ongoing revision process of the influential publication has been cloaked in secrecy. Some critics of the DSM process express other concerns in addition to matters of transparency. It’s been pointed out that about 70% of current task force members have ties to the pharmaceutical industry, up about 14% from DSM-IV.